AIC
ALXN

Ameritas Investment Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Ameritas Investment Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,405
Closed -$740K – 784
2021
Q2 		$740K Sell
2,405
-1,684
-41% -$289K 0.04% 342
2021
Q1 		$625K Buy
4,089
+1,684
+70% +$260K 0.05% 299
2020
Q4 		$376K Buy
+2,405
New +$309K 0.07% 266
2020
Q2 		– Sell
-1,831
Closed -$164K – 1773
2020
Q1 		$164K Buy
1,831
+1,611
+732% +$158K 0.03% 386
2019
Q4 		$24K Sell
220
-1,421
-87% -$152K 0.01% 671
2019
Q3 		$179K Buy
+1,641
New +$185K 0.04% 345
2019
Q2 		– Sell
-1,611
Closed -$218K – 948
2019
Q1 		$218K Buy
1,611
+261
+19% +$32.5K 0.04% 288
2018
Q4 		$131K Buy
+1,350
New +$160K 0.03% 366

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Ameritas Investment Company's ALXN Position: Q3 2021 in Review

Ameritas Investment Company sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,405 shares — an estimated $740K sold.

Ameritas Investment Company first reported a position in ALXN in Q4 2018 and held it in 8 quarters. The position peaked at $740K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Ameritas Investment Company reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ameritas Investment Company sold 2,405 Alexion Pharmaceuticals shares in Q3 2021, an estimated $740K.
  • Ameritas Investment Company first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 8 quarters.
  • Ameritas Investment Company's Alexion Pharmaceuticals position peaked at $740K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Ameritas Investment Company's 13F filing for Q3 2021, filed 12 Nov 2021.